News
SNY
48.27
+0.92%
0.44
Sanofi's Rilzabrutinib Wayrilz Granted FDA Breakthrough Therapy Designation In The US And Orphan Drug Status In Japan For Treatment Of Warm Autoimmune Hemolytic Anemia
Benzinga · 13h ago
Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan
Seeking Alpha · 13h ago
BRIEF-Sanofi Says Rilzabrutinib Designated Breakthrough Therapy In US
Reuters · 14h ago
Sanofi erhält FDA-Breakthrough-Therapie-Status für Rilzabrutinib zur Behandlung von wAIHA
Reuters · 14h ago
Sanofi’s Rilzabrutinib Wins FDA Breakthrough Therapy Status for Rare Anemia
Reuters · 14h ago
Oakmark International Strategy Q4 2025 New Investments And Divestments
Seeking Alpha · 1d ago
Sanofi Wins Positive EU CHMP Opinion for Rezurock in Chronic Graft-Versus-Host Disease
TipRanks · 3d ago
Sanofi’s Rezurock Wins CHMP Backing for EU Approval in Chronic GVHD
Reuters · 3d ago
EMA empfiehlt Zulassung von Sanofis Rezurock zur Behandlung von chronischer GvHD
Reuters · 3d ago
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
TipRanks · 3d ago
Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.
Barron‘s · 3d ago
TRUMPRX.GOV WEBSITE IS LAUNCHED, WEBSITE SHOWS
Reuters · 3d ago
WEBSITE SAYS MANY COMMONLY PRESCRIBED BRAND-NAME DRUGS ARE LISTED ON TRUMPRX, SUCH AS FERTILITY AND WEIGHT LOSS DRUGS
Reuters · 3d ago
TrumpRx website using technology from GoodRx, STAT says
TipRanks · 4d ago
BUZZ-OneSpaWorld jumps as co poised to join S&P SmallCap index
Reuters · 4d ago
Standard Uranium Launches Drilling at Corvo Project After High-Grade Uranium Discovery
Reuters · 4d ago
Standard Uranium startet Bohrungen am Corvo-Uranprojekt mit hochgradigem Manhattan-Vorkommen
Reuters · 4d ago
Aventis Energy startet Bohrprogramm am Corvo-Uranprojekt in Kanada
Reuters · 4d ago
Aventis Energy Launches Drilling at High-Grade Corvo Uranium Project
Reuters · 4d ago
Kepler Capital Sticks to Its Hold Rating for Sanofi (SNYNF)
TipRanks · 4d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.